Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia

Bone Marrow Transplantation volume 38, pages 483–491 (2006)Cite this article

Abstract

A reduced-intensity conditioning allogeneic stem cell transplantation was given to 19 patients (aged 15–59 years) in the first chronic phase and one patient in the accelerated phase with chronic myeloid leukemia (CML) after a regimen consisting of fludarabine (Flu), busulfan (Bu) and ATG Fresenius. The median follow-up was 27 months. Until day +100, no transplant-related mortality was recorded. The incidence of acute and chronic graft-versus-host disease (GvHD) was 55 and 75%, respectively. Two patients (10%) died from GvHD. Fourteen (70%) patients achieved molecular remission. Additional post-transplant intervention (donor lymphocyte infusion, imatinib) was necessary, however, in 10 patients (50% of the patients; non-achievement of stable molecular remission or later relapses). The total direct cost of the transplantation treatment for all of the patients came to 1 572 880 euro. If the patients had been treated with imatinib and followed-up with the same time period as they were following a transplantation, the direct cost of the imatinib treatment would have been 2 005 117 euro. The transplantation treatment appears to be less expensive after approximately 2 years of follow-up. Flu+Bu+ATG is a low-toxicity regimen for patients with CML. However, a close follow-up is necessary and about 50% of the patients require further therapeutic intervention.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Goldman JM, Apperley JF, Jones L, Marcus R, Goolden AW, Batchelor R et al. Bone marrow transplantation for patients with chronic myeloid leukemia. N Engl J Med 1986; 314: 202–207.

    Article  CAS  PubMed  Google Scholar 

  2. Thomas ED, Clift RA, Fefer A, Appelbaum FR, Beatty P, Besinger WI et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Intern Med 1986; 104: 155–163.

    Article  CAS  PubMed  Google Scholar 

  3. Clift RA, Appelbaum FR, Thomas ED . Treatment of chronic myeloid leukemia by marrow transplantation. Blood 1993; 82: 1954–1956.

    CAS  PubMed  Google Scholar 

  4. Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreas E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

    Article  CAS  PubMed  Google Scholar 

  5. Craddock C, Szydlo RM, Klein JP, Dazzi F, Olavarria E, van Rhee F et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and restored to complete remission. Blood 2000; 96: 86–90.

    CAS  PubMed  Google Scholar 

  6. Goldman JM, Gale RP, Horowitz MM, Biggs JC, Champlin RE, Gluckman E et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806–814.

    Article  CAS  PubMed  Google Scholar 

  7. Clift RA, Buckner CD, Appelbaum FR, Bryant E, Bearman SI, Petersen FB et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 77: 1660–1665.

    CAS  PubMed  Google Scholar 

  8. Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 1979; 300: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  9. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  10. Collins Jr RH, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  11. Porter DL, Collins Jr RH, Hardy C, Kernan NA, Drobyski WR, Giralt S et al. Treatment of relapsed leukemia after unrelated donor marrow transplantation with unrelated donor leukocyte infusions. Blood 2000; 95: 1214–1221.

    CAS  PubMed  Google Scholar 

  12. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  13. Childs R, Clave E, Contentin N, Jaysekera D, Hensel N, Leitman S et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241.

    CAS  PubMed  Google Scholar 

  14. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  15. Or R, Shapira MY, Resnick I, Amar A, Ackerstein A, Samuel S et al. Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase. Blood 2003; 101: 441–445.

    Article  CAS  PubMed  Google Scholar 

  16. Sloand E, Childs RW, Solomon S, Greene A, Young NS, Barett AJ . The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia. Bone Marrow Transplant 2003; 32: 897–901.

    Article  CAS  PubMed  Google Scholar 

  17. Kerbauy FR, Storb R, Hegenbart U, Gooley T, Shizuru J, Al-Ali HK et al. Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. Leukemia 2005; 19: 990–997.

    Article  CAS  PubMed  Google Scholar 

  18. Bornhauser M, Kiehl M, Siegert W, Schetelig J, Hertenstein B, Martin H et al. Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis. Br J Haematol 2001; 115: 119–124.

    Article  CAS  PubMed  Google Scholar 

  19. Das M, Saikia TK, Advani SH, Parikh PM, Tawde S . Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia. Bone Marrow Transplant 2003; 32: 125–129.

    Article  CAS  PubMed  Google Scholar 

  20. Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649–654.

    Article  CAS  PubMed  Google Scholar 

  21. Skrepnek GH, Ballard EE . Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach. Pharmacotherapy 2005; 25: 325–334.

    Article  PubMed  Google Scholar 

  22. Lion T . Summary: reports on quantitative analysis of chimerism after allogeneic stem cell transplantation by PCR amplification of microsatellite markers and capillary electrophoresis with fluorescence detection. Leukemia 2003; 17: 232–254.

    Article  Google Scholar 

  23. Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU . Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Philadelphia chromosome-positive patients. Ann Intern Med 1991; 114: 532–538.

    Article  CAS  PubMed  Google Scholar 

  24. Cross NC, Hughes TP, Feng L, O’Shea P, Bungey J, Marks DI et al. Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: correlations with acute graft-versus-host disease and relapse. Br J Haematol 1993; 84: 67–74.

    Article  CAS  PubMed  Google Scholar 

  25. Lion T, Gaiger A, Henn T, Horth E, Haas OA, Geissler K et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon. Leukemia 1995; 9: 1353–1360.

    CAS  PubMed  Google Scholar 

  26. Gabert J, Beillard E, van der Velden VH, Bi W, Grimwade D, Pallisgaard N et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003; 17: 2318–2357.

    Article  CAS  PubMed  Google Scholar 

  27. Raanani P, Dazzi F, Sohal J, Szydlo RM, van Rhee F, Reiter A et al. The rate and kinetics of molecular response to donor leukocyte transfusions in chronic myeloid leukaemia patients treated for relapse after allogeneic bone marrow transplantation. Br J Haematol 1997; 99: 945–950.

    Article  CAS  PubMed  Google Scholar 

  28. Banna GL, Aversa S, Sileni VC, Favaretto A, Ghiotto C, Monfardini S . Nonmyeloablative allogeneic stem cell transplantation (NST) after truly nonmyeloablative and reduced intensity conditioning regimens. Crit Rev Oncol Hematol 2004; 51: 171–189.

    Article  PubMed  Google Scholar 

  29. Basara N, Roemer E, Kraut L, Guenzelmann S, Schmetzer B, Kiehl MG et al. Reduced intensity preparative regimens for allogeneic hematopoietic stem cell transplantation: a single center experience. Bone Marrow Transplant 2002; 30: 651–659.

    Article  CAS  PubMed  Google Scholar 

  30. Mielcarek M, Martin PJ, Leisenring W, Flowers ME, Maloney DG, Sandmaier BM et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756–762.

    Article  CAS  PubMed  Google Scholar 

  31. Baron F, Maris MB, Sandmaier BM, Storer BE, Sorror M, Diaconescu R et al. Graft-versus-tumor effect after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003.

    Article  PubMed  Google Scholar 

  32. Gratwohl A, Brand R, Apperley J, Biezen Av A, Bandini G, Devergie A et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 2002; 100: 3877–3886.

    Article  CAS  PubMed  Google Scholar 

  33. Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S, Parker A et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114.

    Article  CAS  PubMed  Google Scholar 

  34. Martino R, Caballero MD, Canals C, San Miguel J, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341–347.

    Article  CAS  PubMed  Google Scholar 

  35. Junghanss C, Marr KA, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8: 512–520.

    Article  PubMed  Google Scholar 

  36. Fukuda T, Boeckh M, Carter RA, Sandmaier BM, Maris MB, Maloney DG et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827–833.

    Article  CAS  PubMed  Google Scholar 

  37. Hagen EA, Stern H, Porter D, Duffy K, Foley K, Luger S et al. High rate of invasive fungal infections following nonmyeloablative allogeneic transplantation. Clin Infect Dis 2003; 36: 9–15.

    Article  PubMed  Google Scholar 

  38. Mohty M, Jacot W, Faucher C, Bay JO, Zandotti C, Collet L et al. Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen. Leukemia 2003; 17: 2168–2177.

    Article  CAS  PubMed  Google Scholar 

  39. Bacigalupo A . Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects. Bone Marrow Transplant 2005; 35: 225–231.

    Article  CAS  PubMed  Google Scholar 

  40. Meyers JD, Reed CR, Shepp DH, Thornquist M, Dandliker PS, Vicary CA et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogenic marrow transplantation. N Engl J Med 1988; 318: 70–75.

    Article  CAS  PubMed  Google Scholar 

  41. Prentice HG, Gluckman E, Powles RL, Ljungman P, Milpied N, Fernandez Ranada JM et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogenic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group. Lancet 1994; 343: 749–753.

    Article  CAS  PubMed  Google Scholar 

  42. de Lima M, Anagnostopoulos A, Munsell A, Shahjahan M, Ueno N, Ippoliti C et al. Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after hematopoietic stem cell transplantation. Blood 2004; 104: 865–872.

    Article  CAS  PubMed  Google Scholar 

  43. Dalziel K, Round A, Stein K, Garside R, Price A . Effectiveness and cost-effectiveness of imatinib for first-line treatment of chronic myeloid leukaemia in chronic phase: a systematic review and economic analysis. Health Technol Assess 2004; 8: 1–8.

    Article  Google Scholar 

Download references

Acknowledgements

This work was performed in part by the support of the European Leukemia Net and in cooperation with CELL (The CzEch Leukemia Study Group for Life).

Author information

Authors and Affiliations

  1. Department of Internal Medicine – Hematooncology, University Hospital Brno, Brno, Czech Republic

    M Krejci, J Mayer, M Doubek, Y Brychtova, Z Racil, D Dvorakova, M Lengerova, O Horky, Z Koristek & J Vorlicek

  2. Department of Applied Mathematics, Faculty of Science, Masaryk University Brno, Brno, Czech Republic

    Z Pospisil

  3. Department of Pharmacology, 3rd Medical Faculty, Charles University, Prague, Czech Republic

    T Dolezal

Authors
  1. M Krejci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Mayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Doubek
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Brychtova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Z Pospisil
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Z Racil
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. D Dvorakova
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Lengerova
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. O Horky
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Z Koristek
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Dolezal
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J Vorlicek
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Mayer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krejci, M., Mayer, J., Doubek, M. et al. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia. Bone Marrow Transplant 38, 483–491 (2006). https://doi.org/10.1038/sj.bmt.1705478

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705478

Keywords

This article is cited by

Search

Advanced search

Quick links